Seres Therapeutics, Inc. Financial Ratios
MCRB|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Altman Z-Score -4.18 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-825.0%
Profit Margin
-
Net Income / Revenue
Asset Turnover
0.00
Revenue / Total Assets
Equity Multiplier
10.03
Total Assets / Equity
Profitability
Gross Margin
-
Operating Margin
-
EBITDA
-$105.0M
EBITDA Margin
-
Liquidity
Current Ratio
2.56
Quick Ratio
2.56
Solvency
Interest Coverage
-47.55
Efficiency
Asset Turnover
0.00
Inventory Turnover
-
Days Sales Outstanding
-
As of FY2025 · SEC Form 10-K · Last checked Jun 24, 2026
Earnings Quality
Accrual Ratio
+1.5%
+22.2pp YoY
Earnings are roughly in line with operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.